Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer

Anticancer Research

Volumn 25, Issue 2 B, 2005, Pages 1391-1396

  Chiara, Silvana ^a   Nobile, Maria Teresa ^a   Tomasello, Laura ^a   Acquati, Mirko ^a   Taveggia, Paola ^a   Murolo, Carmelina ^a   Percivale, Pierluigi ^a   Rosso, Riccardo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Colorectal cancer; First line chemotherapy; Irinotecan; Phase II study; Raltitrexed

Indexed keywords

ATROPINE; IRINOTECAN; RALTITREXED;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; QUINAZOLINES; SURVIVAL ANALYSIS; THIOPHENES;

EID: 17444412318     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Eng J Med 343: 905-912, 2000.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047, 2000.
3. Bouzid K, Khalfallah S, Tujakowski J, Piko B, Purkalne G, Plate S, Padrik P, Serafy M, Pshevloutsky EM and Boussard B: Irinotecan Study Group: A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol 14: 1106-1114, 2003.
4. Anand AJ: Fluorouracil cardiotoxicity. Ann Pharmacother 28: 374-378, 1994.
5. Lu Z, Zhang R and Diasio RB: DPD activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-FU chemotherapy. Cancer Res 53: 5433-5438, 1993.
6. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G et al: "Tomudex" (ZD1694): results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31: 1945-1954, 1995.
7. Feliu J, Mel JR, Camps C, Escudero P, Aparicio J, Menendez D, Garcia Giron C, Rodriguez MR, Sanchez JJ and Gonzalez Baron M: Oncopaz Cooperative Group Associated Hospitals: Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. Eur J Cancer 38: 1204-1211, 2002.
8. Kohne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, Bauer B, Dietz R and Dorken B: Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 77: 973-977, 1998.
9. Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG and Bertino JR: Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res 4: 1323-1330, 1998.
10. Ford HE, Cunningham D, Ross PJ, Rao S, Aherne GW, Benepal TS, Price T, Massey A, Vernillet L and Gruia G: Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. Br J Cancer 83: 146-152, 2000.
11. Stevenson JP, Redlinger M, Kluijtmans LA, Sun W, Algazy K, Giantonio B, Haller DG, Hardy C, Whitehead AS and O'Dwyer PJ: Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol 19: 4081-4087, 2001.
12. Aparicio J, de las Penas R, Vicent JM, Garcera S, Llorca C, Maestu I, Yuste AL and Farres J: Multicenter phase I study: irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Oncology 63: 42-47, 2002.
13. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0 Bethesda, MD: National Cancer Institute, 1998.
14. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
15. Wadler S, Benson AB 3rd, Engelking C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P and Vokes E: Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16: 3169-3178, 1998.
16. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
17. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E and Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807, 2001.
18. Carnaghi C, Rimassa L, Garassino I, Zucali PA, Masci G, Fallini M, Morenghi E and Santoro A: Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. Ann Oncol 13: 1424-1429, 2002.
19. Feliu J, Salud A, Escudero P, Lopez-Gomez L, Pericay C, Castanon C, de Tejada MR, Rodriguez-Garcia JM, Martinez MP, Martin MS, Sanchez JJ and Baron MG: Oncopaz Cooperative Group and Associated Hospitals: irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. Br J Cancer 90: 1502-1507, 2004.
20. Aparicio J, Vicent JM, Maestu I, Garcera S, Busquier I, Bosch C, Llorca C, Diaz R, Fernandez-Martos C and Galan A: Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Ann Oncol 14: 1121-1125, 2003.
21. García Girón C, Salut A, Sanchez-Rovira P, Benavides M, Gonzalez E, Jiménez E, Arizcun A, Murias A, Moreno AL and Balcells M: Phase II trial of irinotecan (IRI) and raltitrexed (RTD) administered every two weeks in chemotherapy naive advanced colorectal cancer (ACRC) patients. Proc Am Soc Clin Oncol 21: 172a (abstract 685).
22. Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G and Lissoni P: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 23: 1951-4, 2003.
23. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-45, 2004.